Construction of tissue-engineered cartilage using human placenta-derived stem cells

Liu, DaShun; Hui, Hongxiang; Chai, Xiang－bin; Wang, BinQuan; Qiu, Jianhua

doi:10.1007/s11427-010-0016-5

Cited by 12 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, MSCs derived from umbilical cord blood have unavoidable immunogenicity, and the there is a limited amount of amniotic fluid that is available. Therefore, PL‐MSCs are a good choice when relative to any of the other sources [Li et al, ; Liu et al, ]. For these reasons, BM‐, PL‐, and AT‐MSCs have been widely used in clinical applications, such as transplantation therapy.…”

Section: Discussionmentioning

confidence: 99%

Comparative Analysis of Human Mesenchymal Stem Cells Derived From Bone Marrow, Placenta, and Adipose Tissue as Sources of Cell Therapy

Jeon

Kim

Cho

et al. 2015

J of Cellular Biochemistry

View full text Add to dashboard Cite

Various source-derived mesenchymal stem cells (MSCs) with multipotent capabilities were considered for cell therapeutics of incurable diseases. The applicability of MSCs depends on the cellular source and on their different in vivo functions, despite having similar phenotypic and cytological characteristics. We characterized MSCs from different sources, including human bone marrow (BM), placenta (PL), and adipose tissue (AT), in terms of the phenotype, surface antigen expression, differentiation ability, proteome reference map, and blood flow recovery in a hindlimb ischemic disease model. The MSCs exhibit different differentiation potentials depending on the cellular source despite having similar phenotypic and surface antigen expression. We identified approximately 90 differentially regulated proteins. Most up- or down-regulated proteins show cytoskeletal or oxidative stress, peroxiredoxin, and apoptosis roles according to their functional involvement. In addition, the PL-MSCs retained a higher therapeutic efficacy than the BM- and AT-MSCs in the hindlimb ischemic disease model. In summary, we examined differentially expressed key regulatory factors for MSCs that were obtained from several cellular sources and demonstrated their differentially expressed proteome profiles. Our results indicate that primitive PL-MSCs have biological advantages relative to those from other sources, making PL-MSCs a useful model for clinical applications of cell therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Analysis of Human Mesenchymal Stem Cells Derived From Bone Marrow, Placenta, and Adipose Tissue as Sources of Cell Therapy

Jeon

Kim

Cho

et al. 2015

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…Besides differentiating into the characteristic mesodermal lineages (osteogenic, chondrogenic, adipogenic), AMSC have the ability to differentiate into other cell types, such as neural and glial cells, skeletal muscle cells, cardiomyocytes, pancreatic and hepatic cells [21]. AM-MSCs have been used to treat lung fibrosis [22] and musculoskeletal disorders [23].…”

Section: Amniotic Membranementioning

confidence: 99%

Current Status and Future Prospects of Perinatal Stem Cells

Torre

Flores

2020

Genes

View full text Add to dashboard Cite

The placenta is a temporary organ that is discarded after birth and is one of the most promising sources of various cells and tissues for use in regenerative medicine and tissue engineering, both in experimental and clinical settings. The placenta has unique, intrinsic features because it plays many roles during gestation: it is formed by cells from two individuals (mother and fetus), contributes to the development and growth of an allogeneic fetus, and has two independent and interacting circulatory systems. Different stem and progenitor cell types can be isolated from the different perinatal tissues making them particularly interesting candidates for use in cell therapy and regenerative medicine. The primary source of perinatal stem cells is cord blood. Cord blood has been a well-known source of hematopoietic stem/progenitor cells since 1974. Biobanked cord blood has been used to treat different hematological and immunological disorders for over 30 years. Other perinatal tissues that are routinely discarded as medical waste contain non-hematopoietic cells with potential therapeutic value. Indeed, in advanced perinatal cell therapy trials, mesenchymal stromal cells are the most commonly used. Here, we review one by one the different perinatal tissues and the different perinatal stem cells isolated with their phenotypical characteristics and the preclinical uses of these cells in numerous pathologies. An overview of clinical applications of perinatal derived cells is also described with special emphasis on the clinical trials being carried out to treat COVID19 pneumonia. Furthermore, we describe the use of new technologies in the field of perinatal stem cells and the future directions and challenges of this fascinating and rapidly progressing field of perinatal cells and regenerative medicine.

show abstract

“…Some systems have shown suitable behaviors as recipients of PMSC for cartilage regeneration. Collagen sponge allowed the formation of a cartilage-like tissue both, in vitro and in vivo, under chondrogenic-inducing conditions [95]. Similarly, PMSC embedded in alginate incorporating nanosized calcium-deficient hydroxyapatite (nCDHA) and/or a recombinant protein containing arginine-glycine-aspartate (RGD) and seeded over poly(D,L-lactide-co-glycolide) (PLGA) gave rise to cartilage formation [96].…”

Section: Use Of Placenta Mesenchymal Stem/stromal Cells (Pmsc) and Namentioning

confidence: 99%

Human Placenta-Derived Mesenchymal Stromal Cells: A Review from Basic Research to Clinical Applications

Torre¹,

Pérez-Lorenzo²,

Flores³

2019

Stromal Cells - Structure, Function, and Therapeutic Implications

View full text Add to dashboard Cite

Placenta-derived mesenchymal stem/stromal cells (PMSC) present several aspects that make them more attractive as cellular therapy than their counterparts from other tissues, such as MSC from bone marrow or adipose tissue in regenerative medicine. Placenta-derived MSC have been used to treat a variety of disorders, such as, cancer, liver and cardiac diseases, ulcers, bone repair, and neurological diseases. Placenta-derived MSC are relatively new types of MSC with specific immunomodulatory properties and whose mechanisms are still unknown. Placenta-derived MSC secrete some soluble factors that seem to be responsible for their therapeutic effects, i.e., they have paracrine effects. On the other hand, Placentaderived MSC can also serve as cellular vehicles and/or delivery systems for medications due to their migration capacity and their tropism for injury sites. Nanotechnology is an important field, which has undergone rapid development in recent years for the treatment of injured organs. Due to the special characteristics of placenta-derived MSC, the combination of these cells with nanotechnology will be a significant and highly promising field that will provide significant contributions in the regenerative medicine field in the near future.

show abstract

Construction of tissue-engineered cartilage using human placenta-derived stem cells

Cited by 12 publications

References 17 publications

Comparative Analysis of Human Mesenchymal Stem Cells Derived From Bone Marrow, Placenta, and Adipose Tissue as Sources of Cell Therapy

Comparative Analysis of Human Mesenchymal Stem Cells Derived From Bone Marrow, Placenta, and Adipose Tissue as Sources of Cell Therapy

Current Status and Future Prospects of Perinatal Stem Cells

Human Placenta-Derived Mesenchymal Stromal Cells: A Review from Basic Research to Clinical Applications

Contact Info

Product

Resources

About